News Release

Semaglutide and hospitalizations in patients with obesity and established cardiovascular disease

JAMA Cardiology

Peer-Reviewed Publication

JAMA Network

About The Study: In this prespecified exploratory analysis of the SELECT randomized clinical trial, the trial cohort had a high rate of hospital admissions. Treatment with once-weekly semaglutide was associated with significant reductions in hospital admissions and overall time spent in hospital, extending its benefits beyond cardiovascular risk reduction.

Corresponding Author: To contact the corresponding author, Stephen J. Nicholls, MD, email stephen.nicholls@monash.edu.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jamacardio.2025.4824)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.

#  #  #

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time
https://jamanetwork.com/journals/jamacardiology/fullarticle/10.1001/jamacardio.2025.4824?guestAccessKey=7b8e8f70-d1ce-4331-a5fc-a0867b7b6fe7&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=122325 


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.